{"id":"filgrastim-eurofarma","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Bone pain"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Fatigue"},{"rate":"5-15","effect":"Injection site reactions"},{"rate":"5-10","effect":"Splenomegaly"},{"rate":"5-10","effect":"Elevated uric acid"}]},"_chembl":{"chemblId":"CHEMBL1201567","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Filgrastim binds to G-CSF receptors on hematopoietic cells, promoting the growth and maturation of neutrophils from bone marrow precursors. This increases circulating neutrophil counts, helping to reduce the risk and duration of infection in patients with chemotherapy-induced neutropenia or other conditions causing low white blood cell counts.","oneSentence":"Filgrastim is a granulocyte colony-stimulating factor (G-CSF) that stimulates the proliferation and differentiation of neutrophil progenitor cells in bone marrow.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:12:34.781Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chemotherapy-induced neutropenia"},{"name":"Severe chronic neutropenia"},{"name":"Mobilization of peripheral blood progenitor cells for autologous transplantation"}]},"trialDetails":[{"nctId":"NCT01079676","phase":"PHASE3","title":"A Non-inferiority Study Comparing Two Filgrastim Preparations in Breast Cancer","status":"COMPLETED","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2011-03","conditions":"Neutropenia in Breast Cancer","enrollment":220}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Filgrastim (Eurofarma)","genericName":"Filgrastim (Eurofarma)","companyName":"Eurofarma Laboratorios S.A.","companyId":"eurofarma-laboratorios-s-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Filgrastim is a granulocyte colony-stimulating factor (G-CSF) that stimulates the proliferation and differentiation of neutrophil progenitor cells in bone marrow. Used for Chemotherapy-induced neutropenia, Severe chronic neutropenia, Mobilization of peripheral blood progenitor cells for autologous transplantation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}